Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search

PCSK9

Protein-coding gene in the species homo sapiens

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
BioSpace
June 23, 2021
BioSpace
Draupnir Bio, a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, announces the appointment of Andrew Hotchkiss as Chief Executive Officer.
Bob Yirka
May 21, 2021
phys.org
A team of researchers from Verve Therapeutics and the Perelman School of Medicine at the University of Pennsylvania has developed a CRISPR gene-editing technique that lowered the levels of cholesterol in the blood of test monkeys. In their paper published in the journal Nature, the researchers describe their technique.
BioSpace
May 11, 2021
BioSpace
Verve Therapeutics announced the presentation of additional preclinical data from the company's gene editing programs for the treatment of atherosclerotic cardiovascular disease, the most common form of cardiovascular disease, at the American Society of Gene and Cell Therapy 24th Virtual Annual Meeting.
BioSpace
May 5, 2021
BioSpace
Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sheila Mikhail, J.D., MBA, chief executive officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio),
Angus Liu
April 21, 2021
FierceBiotech
Scientists at AstraZeneca have early data showing that an experimental antibody drug increases "good" HDL cholesterol in monkeys and people. Combining the drug with a PCSK9 inhibitor appeared to have a synergistic effect.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.